Reckitt Benckiser Pharmaceuticals has entered into a definitive agreement with AntiOp, Inc. to co-develop a naloxone nasal spray for the reversal of opioid overdose, with the option to acquire all rights to the product upon regulatory approval. The product has the potential to be the first of its kind to treat overdose from opioid prescription painkillers and heroin.
The current standard medical protocol for treating opioid overdose is to administer an injectable form of naloxone.This product aims to provide an alternative for family members and caregivers with a nasal administration utilizing AntiOp’s medication delivery expertise. AntiOp's nasal formulation is a pre-filled, unit-dose, disposable delivery system. The needle-free device was selected to facilitate broader access to this treatment
"This strategic agreement partners the innovative science of AntiOp, led by Dr. Daniel Wermeling, renowned for his work in the nasal delivery of medication, with the leadership of Reckitt Benckiser Pharmaceuticals as an innovator in opioid dependence treatment for more than a decade," said Shaun Thaxter, chief executive officer of Reckitt Benckiser. "Together, we are uniquely suited to bring this product to market and are excited about the potential to help the many patients each year who succumb to opioid overdose. Naloxone nasal spray is a strong, strategic fit to our portfolio further strengthening our capabilities to provide much needed treatment services for the chronic relapsing conditions of addiction."